Capricor Therapeutics Inc... (CAPR)
NASDAQ: CAPR
· Real-Time Price · USD
12.31
0.53 (4.50%)
At close: Jun 16, 2025, 3:59 PM
12.76
3.66%
After-hours: Jun 16, 2025, 06:36 PM EDT
4.50% (1D)
| Bid | 12.5 |
| Market Cap | 562.66M |
| Revenue (ttm) | 17.36M |
| Net Income (ttm) | -55.06M |
| EPS (ttm) | -1.37 |
| PE Ratio (ttm) | -8.99 |
| Forward PE | -26.3 |
| Analyst | Buy |
| Ask | 12.85 |
| Volume | 2,089,741 |
| Avg. Volume (20D) | 2,172,023 |
| Open | 12.11 |
| Previous Close | 11.78 |
| Day's Range | 11.75 - 12.40 |
| 52-Week Range | 3.52 - 23.40 |
| Beta | 0.85 |
About CAPR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CAPR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CAPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-29.13%
Shares of vaccine and gene therapy stocks are trad...
Unlock content with
Pro Subscription
1 month ago
-13.15%
Capricor Therapeutics shares are trading lower. The company announced the completion of a mid-cycle review meeting with the FDA for the Company's Biologics License Application seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy.
